Citable filing context
LH's research view summarizes recent SEC filing context, starting with other from Aug 17, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 17, 2026 | other | Labcorp announced it will host an Investor Day on September 10, 2026. |
| Aug 14, 2026 | management_change | Megan D. Bailey will resign as EVP and President, Central Laboratories and International, effective September 4, 2026. |
| Jul 30, 2026 | earnings | Labcorp reported Q2 2026 revenue of $3.73 billion, up 5.8%, and raised its full-year 2026 financial guidance. |
| Jul 30, 2026 | Guidance: adjusted_eps | 18.10 to 18.55 |
| Jul 30, 2026 | Guidance: free_cash_flow | 1240.00 to 1360.00 |
| Jul 30, 2026 | Guidance: revenue | 14710.00 to 14827.00 |
| Aug 5, 2026 | mda_quarterly | Labcorp Holdings Inc. reported a 5.8% revenue increase for the second quarter of 2026, reaching $3.73 billion, driven by 4.2% organic growth and contributions from acquisitions. The Diagnostics (Dx) segment, which accounts for the majority of revenue, grew 5.5% due to a 3.0% increase in requisition volume and a 2.5% improvement in price/mix. The Biopharma Laboratory Services (BLS) segment saw a 6.5% revenue increase, bolstered by strong organic growth in the Central Laboratory business. Operating margins expanded in both segments, with Dx rising 50 basis points to 18.0% and BLS rising 130 basis points to 17.0%, reflecting improved operating efficiencies. Liquidity remains robust, supported by $637 million in operating cash flow for the first half of 2026. The company maintains access to a $1 billion revolving credit facility and recently secured a $750 million term loan to refinance senior notes. Capital allocation remains focused on growth, with $252.6 million in capital expenditures and a significant share repurchase program, recently expanded by $1 billion. Management continues to monitor regulatory risks, including the OBBBA legislation, and potential impacts from shifts in payer reimbursement and patient cost-sharing, though they currently anticipate no material disruption to operations. |
| May 4, 2026 | mda_quarterly | Labcorp Holdings Inc. reported revenues of $3.54 billion for the first quarter of 2026, a 5.8% increase year-over-year. This growth was driven by 3.1% organic revenue expansion, 1.4% from net acquisitions, and 1.3% from favorable foreign currency translation. The Diagnostics (Dx) segment grew 5.0% to $2.76 billion, supported by a 2.5% increase in total requisition volume, while the Biopharma Laboratory Services (BLS) segment rose 8.2% to $780.6 million, bolstered by Central Laboratory business performance. Operating margins improved across both segments, with Dx rising 30 basis points to 16.6% and BLS rising 60 basis points to 15.5%. Cost of revenue as a percentage of total revenue declined to 71.3% due to operating efficiencies. Liquidity remains robust, with $981.1 million in cash and $1 billion available under a revolving credit facility. Financing activities included the issuance of a $750 million term loan maturing in 2028. Management is monitoring the July 2025 OBBBA legislation, which could impact diagnostic utilization through potential changes to Medicaid and the Affordable Care Act. Key risks include regulatory shifts in healthcare reimbursement, potential impacts from the SYNLAB investment, and ongoing integration of acquisitions, such as the pending Parkview outreach business assets. |
Source: SEC EDGAR filing text and events; period Aug 17, 2026; filed Aug 17, 2026.
LH company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.